We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
Investors' focus will be on the sales performance of Firdapse when Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reports third-quarter 2019 earnings results.
The company’s earnings track record has been mixed so far, having delivered a positive surprise twice in the trailing four quarters while missing the same once and delivering in-line results in another quarter, the average beat being 77.24%. In the last reported quarter, Catalyst came up with a positive surprise of 233.33%.
Shares of Catalyst have skyrocketed 193.8% year to date compared with the industry’s increase of 1.5%.
Let’s see how things are shaping up for the upcoming quarterly results.
Factors to Consider
Catalyst’s only marketed drug Firdapse was launched in the United States in January 2019 after receiving the FDA approval in November 2018. The drug was approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse became the first FDA approved treatment for LEMS.
Firdapse was off to a solid start soon after its launch and recorded sales of $28.8 million in the second quarter of 2019, reflecting 132.3% growth sequentially. In the same period, revenues were entirely drawn from Firdapse. The drug is likely to have performed well and contributed to significant revenues in the third quarter as well.
Per the company, Firdapse is prescribed to 409 LEMS patients as of Jun 30, 2019. It remains to be seen whether the number of patients active on Firdapse went up in the third quarter in the impending results.
Update on Firdapse Studies
Meanwhile, Catalyst is working on developing Firdapse for additional indications. The company is currently conducting phase III studies on the drug for treating congenital myasthenic syndromes (CMS) and anti-MuSK-antibody positive myasthenia gravis (MuSK-MG). It expects to complete enrollment in the MuSK-MG study during the second half of 2019 and report top-line results in the first half of 2020.
The company expects to report top-line results from the phase III CMS study in the second half of 2019.
Catalyst is also conducting a proof-of-concept study, evaluating Firdapse as a symptomatic treatment for patients with SMA type III. Top-line results are expected in the first half of 2020.
Investors will be keen to get an update on all these studies during the upcoming earnings call as a potential label expansion will boost the drug’s sales in the future quarters.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Catalyst this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Catalyst has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at 11 cents per share.
Zacks Rank: Catalyst carries a Zacks Rank #2, which increases the predictive power of ESP. However, the 0.00% ESP makes surprise prediction difficult.
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise
Jazz Pharmaceuticals PLC (JAZZ - Free Report) has an Earnings ESP of +1.70% and is Zacks #2 Ranked. The company is scheduled to release results on Nov 5.
Portola Pharmaceuticals, Inc. has an Earnings ESP of +6.33% and a Zacks Rank of 1. The company is scheduled to release results on Nov 5.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
Investors' focus will be on the sales performance of Firdapse when Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reports third-quarter 2019 earnings results.
The company’s earnings track record has been mixed so far, having delivered a positive surprise twice in the trailing four quarters while missing the same once and delivering in-line results in another quarter, the average beat being 77.24%. In the last reported quarter, Catalyst came up with a positive surprise of 233.33%.
Shares of Catalyst have skyrocketed 193.8% year to date compared with the industry’s increase of 1.5%.
Let’s see how things are shaping up for the upcoming quarterly results.
Factors to Consider
Catalyst’s only marketed drug Firdapse was launched in the United States in January 2019 after receiving the FDA approval in November 2018. The drug was approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse became the first FDA approved treatment for LEMS.
Firdapse was off to a solid start soon after its launch and recorded sales of $28.8 million in the second quarter of 2019, reflecting 132.3% growth sequentially. In the same period, revenues were entirely drawn from Firdapse. The drug is likely to have performed well and contributed to significant revenues in the third quarter as well.
Per the company, Firdapse is prescribed to 409 LEMS patients as of Jun 30, 2019. It remains to be seen whether the number of patients active on Firdapse went up in the third quarter in the impending results.
Update on Firdapse Studies
Meanwhile, Catalyst is working on developing Firdapse for additional indications. The company is currently conducting phase III studies on the drug for treating congenital myasthenic syndromes (CMS) and anti-MuSK-antibody positive myasthenia gravis (MuSK-MG). It expects to complete enrollment in the MuSK-MG study during the second half of 2019 and report top-line results in the first half of 2020.
The company expects to report top-line results from the phase III CMS study in the second half of 2019.
Catalyst is also conducting a proof-of-concept study, evaluating Firdapse as a symptomatic treatment for patients with SMA type III. Top-line results are expected in the first half of 2020.
Investors will be keen to get an update on all these studies during the upcoming earnings call as a potential label expansion will boost the drug’s sales in the future quarters.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Catalyst this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Catalyst has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at 11 cents per share.
Zacks Rank: Catalyst carries a Zacks Rank #2, which increases the predictive power of ESP. However, the 0.00% ESP makes surprise prediction difficult.
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise
Catalyst Pharmaceuticals, Inc. price-eps-surprise | Catalyst Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank of 2. The company is scheduled to release results on Oct 31.You can see the complete list of today’s Zacks #1 Rank stocks here.
Jazz Pharmaceuticals PLC (JAZZ - Free Report) has an Earnings ESP of +1.70% and is Zacks #2 Ranked. The company is scheduled to release results on Nov 5.
Portola Pharmaceuticals, Inc. has an Earnings ESP of +6.33% and a Zacks Rank of 1. The company is scheduled to release results on Nov 5.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>